Khiron Life Sciences Corp. (KHRNF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
KHRNF representa a Khiron Life Sciences Corp., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 59/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Khiron Life Sciences Corp. (KHRNF) Resumen de Asistencia Médica y Tuberías
Khiron Life Sciences Corp. is an integrated medical cannabis company operating in Latin America and Europe. It distinguishes itself through its cultivation, production, and distribution of medical cannabis, coupled with a network of health centers and CBD-based cosmeceutical products, positioning it within the evolving global cannabis market.
Tesis de Inversión
Khiron Life Sciences Corp. presents an investment opportunity within the expanding medical cannabis market in Latin America and Europe. The company's integrated business model, encompassing cultivation, production, distribution, and clinic operations, offers potential for revenue diversification and market penetration. A key value driver is the increasing acceptance and legalization of medical cannabis in target markets, which could drive demand for Khiron's products and services. Growth catalysts include expanding the network of Zerenia clinics and developing new CBD-based products. However, potential risks include regulatory uncertainties, competition from other cannabis companies, and the company's current negative profit margin of -258.9%. Investors should monitor the company's ability to achieve profitability and navigate the evolving regulatory landscape.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Operates in the rapidly growing medical cannabis market in Latin America and Europe.
- Integrated business model encompassing cultivation, production, distribution, and clinic operations.
- Gross margin of 22.5% indicates potential for profitability with increased scale.
- Network of health centers and satellite clinics under the ILANS and Zerenia brands provides a direct channel to patients.
- Development of CBD-based cosmeceutical products under the Kuida brand diversifies revenue streams.
Competidores y Pares
Fortalezas
- Integrated business model.
- Established presence in Latin America and Europe.
- Network of health centers and satellite clinics.
- Development of CBD-based cosmeceutical products.
Debilidades
- Negative profit margin.
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition.
Catalizadores
- Upcoming: Expansion of Zerenia clinic network to new locations in Latin America and Europe.
- Ongoing: Increasing legalization and acceptance of medical cannabis in target markets.
- Ongoing: Development and launch of new CBD-based products.
- Ongoing: Strategic partnerships with pharmaceutical companies and healthcare providers.
- Upcoming: Securing regulatory approvals for medical cannabis products in new countries.
Riesgos
- Potential: Regulatory uncertainties and changes in cannabis laws.
- Ongoing: Competition from established pharmaceutical companies and other cannabis companies.
- Potential: Fluctuations in cannabis prices and supply chain disruptions.
- Ongoing: Negative profit margin and limited financial resources.
- Potential: Economic downturns and reduced consumer spending.
Oportunidades de crecimiento
- Expansion of Zerenia Clinics: Khiron can expand its network of Zerenia clinics across Latin America and Europe. Each new clinic increases patient access to medical cannabis treatments, driving revenue growth. The medical cannabis market in Latin America is projected to grow significantly, offering a substantial opportunity for Khiron to capture market share through clinic expansion. Timeline: Ongoing.
- Development of New CBD Products: Khiron can develop and launch new CBD-based products, including cosmeceuticals and wellness products. The global CBD market is experiencing rapid growth, driven by increasing consumer awareness of the potential health benefits of CBD. This presents a significant opportunity for Khiron to diversify its revenue streams and expand its customer base. Timeline: Ongoing.
- Strategic Partnerships: Khiron can form strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers to expand its reach and access new markets. Partnerships can provide access to new technologies, distribution channels, and patient populations. This can accelerate Khiron's growth and enhance its competitive position. Timeline: Ongoing.
- Regulatory Approvals: Securing regulatory approvals for its medical cannabis products in new markets can drive significant revenue growth for Khiron. As more countries legalize medical cannabis, Khiron can expand its geographic footprint and access new patient populations. This requires navigating complex regulatory processes and demonstrating the safety and efficacy of its products. Timeline: Ongoing.
- International Exports: Khiron can increase its exports of medical cannabis products to international markets. The global medical cannabis market is expanding rapidly, creating opportunities for Khiron to supply its products to countries with limited domestic production capacity. This requires establishing international distribution networks and complying with export regulations. Timeline: Ongoing.
Oportunidades
- Expansion of Zerenia clinics.
- Development of new CBD products.
- Strategic partnerships.
- International exports.
Amenazas
- Regulatory uncertainties.
- Competition from established pharmaceutical companies.
- Fluctuations in cannabis prices.
- Economic downturns.
Ventajas competitivas
- Integrated business model encompassing cultivation, production, distribution, and clinic operations.
- Established network of health centers and satellite clinics.
- Brand recognition in Latin America and Europe.
- Expertise in cultivating and producing high-quality medical cannabis.
Acerca de KHRNF
Khiron Life Sciences Corp., established in 2012 and headquartered in Vancouver, Canada, operates as an integrated medical cannabis company with a focus on Latin America and Europe. The company's business is structured around three segments: Health Services, Medical Cannabis Products, and Wellbeing Products. Khiron cultivates, produces, distributes, and exports tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company has established a network of health centers and satellite clinics under the ILANS and Zerenia brands, providing medical cannabis consultations and treatments. Additionally, Khiron develops and markets CBD-based cosmeceutical products under the Kuida brand. Its operations include a Zerenia clinic in Medellin, Colombia, and Peru, expanding access to medical cannabis treatments in the region. Khiron aims to establish itself as a leader in the Latin American and European medical cannabis markets by integrating cultivation, production, distribution, and patient care.
Qué hacen
- Cultivates and produces medical cannabis.
- Distributes and exports medical cannabis products.
- Operates a network of health centers and satellite clinics under the ILANS and Zerenia brands.
- Develops CBD-based cosmeceutical products under the Kuida brand name.
- Provides medical cannabis consultations and treatments.
- Operates Zerenia clinics in Medellin and Peru.
Modelo de Negocio
- Cultivation and production of medical cannabis.
- Distribution and sale of medical cannabis products through clinics and other channels.
- Provision of medical consultations and treatments at Zerenia clinics.
- Sale of CBD-based cosmeceutical products.
Contexto de la Industria
Khiron Life Sciences Corp. operates in the burgeoning medical cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical purposes. The global medical cannabis market is projected to reach billions of dollars in the coming years. Khiron competes with other cannabis companies, including ANTCF (Antibe Therapeutics Inc.), BSPK (Bioscience Properties Inc.), EVIO (EVIO Inc.), GENPF (General Cannabis Corp), and HEMP (HEMP, Inc.), as well as established pharmaceutical companies exploring cannabis-based treatments. Khiron's focus on Latin America and Europe differentiates it from competitors primarily focused on North America.
Clientes Clave
- Patients seeking medical cannabis treatments.
- Consumers of CBD-based cosmeceutical products.
- Healthcare providers prescribing medical cannabis.
- Distributors of medical cannabis products.
Finanzas
Gráfico e información
Precio de la acción de Khiron Life Sciences Corp. (KHRNF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Friday
· 28 feb 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27 feb 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· 26 feb 2020
-
Stocks That Hit 52-Week Lows On Friday
· 8 nov 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para KHRNF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para KHRNF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de KHRNF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Alvaro Francisco Torres
CEO
Alvaro Francisco Torres serves as the CEO of Khiron Life Sciences Corp. His background includes experience in the healthcare and pharmaceutical industries. He has a proven track record of leading and growing companies in emerging markets. His expertise spans strategic planning, business development, and operational management. He is responsible for overseeing all aspects of Khiron's business, including cultivation, production, distribution, and clinic operations.
Historial: Under Alvaro Francisco Torres' leadership, Khiron Life Sciences Corp. has expanded its operations in Latin America and Europe, established a network of Zerenia clinics, and developed CBD-based cosmeceutical products. He has overseen the company's efforts to secure regulatory approvals for its medical cannabis products in various countries. His strategic decisions have positioned Khiron as a leader in the Latin American medical cannabis market.
Información del mercado OTC de KHRNF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Khiron Life Sciences Corp. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading can be more speculative. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet the requirements of higher tiers. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited disclosure and transparency due to the OTC Other tier listing.
- Higher price volatility due to lower trading volumes and liquidity.
- Potential for fraudulent or manipulative activities.
- Lack of regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable information about the company's financial performance.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Operations in the regulated medical cannabis industry.
- Network of health centers and satellite clinics under established brands.
- Development of CBD-based cosmeceutical products.
- Presence in Latin America and Europe.
- CEO with experience in the healthcare and pharmaceutical industries.
Acciones de Khiron Life Sciences Corp.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar KHRNF?
Khiron Life Sciences Corp. (KHRNF) actualmente tiene una puntuación IA de 59/100, indicando puntuación moderada. Fortaleza clave: Integrated business model.. Riesgo principal a monitorear: Potential: Regulatory uncertainties and changes in cannabis laws.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de KHRNF?
KHRNF actualmente puntúa 59/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de KHRNF?
Los precios de KHRNF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre KHRNF?
La cobertura de analistas para KHRNF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en KHRNF?
Las categorías de riesgo para KHRNF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory uncertainties and changes in cannabis laws.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de KHRNF?
La relación P/E para KHRNF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está KHRNF sobrevalorada o infravalorada?
Determinar si Khiron Life Sciences Corp. (KHRNF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de KHRNF?
Khiron Life Sciences Corp. (KHRNF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.